Economy Apr 01 Stocks rally worldwide and oil prices ease on the hopes for a possible end to Iran war By Stan Choe, Associated Press
Health Apr 01 FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity The Food and Drug Administration's decision Wednesday means patients in the United States will soon have access to a second daily oral medication to treat obesity and weight-related issues. By JoNel Aleccia, Associated Press
Politics Nov 06 WATCH: Trump announces deal to expand coverage, lower costs on obesity drugs President Donald Trump unveiled a deal Thursday with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for the popular obesity treatments Zepbound and Wegovy. By Tom Murphy, Aamer Madhani, JoNel Aleccia, Associated Press
Health Mar 05 Novo Nordisk cuts Wegovy prices, following Eli Lilly on Zepbound The new monthly price of $499, down from $650, takes effect immediately. By Associated Press
Health Jul 02 FDA approves 2nd Alzheimer's drug that can modestly slow dementia Kisunla is not a cure and slows worsening memory and cognitive problems by about seven months. By Matthew Perrone, Associated Press
Jun 10 FDA advisers back Alzheimer's drug that can slow disease By Matthew Perrone, Associated Press If the agency agrees with the panel's recommendation, the drug, donanemab, would only be the second Alzheimer’s drug cleared in the U.S. shown to convincingly slow cognitive decline and memory problems due to Alzheimer's. Continue reading
Jul 17 A 2nd experimental Alzheimer's drug shows promise, but comes with safety risks By Lauran Neergaard, Associated Press If U.S. regulators approve, the drug would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding. Continue reading
Mar 14 Novo Nordisk plans major price cuts for several insulins By Tom Murphy, Associated Press The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions. They include Levemir, Novolin, NovoLog and NovoLog Mix70/30. Continue reading
Mar 05 Analysis: Eli Lilly is capping insulin copays at $35. Here are 5 questions answered By Dana Goldman, Karen Van Nuys, The Conversation Two scholars who have researched insulin pricing explain why Eli Lilly is dramatically cutting the cost of some of its insulin products and how it may improve access to this essential medical treatment. Continue reading
Mar 01 Watch 5:12 Pharmaceutical giant slashes insulin prices after pressure from government and consumers By Geoff Bennett, Courtney Norris More than seven million Americans rely on insulin and prices for the life-saving drug have sky-rocketed. With pressure mounting on pharmaceutical companies to address the cost of diabetes care, Eli Lilly announced it’s cutting prices for its most popular insulin… Continue watching